Abstract Type 2 diabetes (T2DM) is a leading cause of morbidity and mortality worldwide
and a major economic burden. The prevalence of T2DM is rising, suggesting more effective …

Background A wide variety of oral diabetes medications are currently available for the
treatment of type 2 diabetes mellitus, but it is unclear how these agents compare with …

ContextPatients with diabetes mellitus account for approximately 25% of the nearly 1.5
million coronary revascularization procedures performed each year in the United States and …

Background In patients with type 2 diabetes mellitus, all therapeutic options should be
evaluated for their effect on cardiovascular risk factors, in addition to glycemic control. We …

Pioglitazone improves glycaemic control, not only by lowering insulin resistance, but also by
improving beta cell function. Because of the improved beta cell function the glycaemic …

Cardiovascular disorders are the major cause of mortality in patients of diabetes mellitus.
Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription …

OBJECTIVE—The PROspective pioglitAzone Clinical Trial In macroVascular Events
(PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor …

Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance,
increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic …

Objectives: The purpose of this study was to test the safety and efficacy of pioglitazone and
simvastatin in combination versus each drug individually in non-diabetic subjects with …

OBJECTIVE—Despite the popularity of coronary stenting in coronary artery disease (CAD),
restenosis remains a challenging clinical problem. This study evaluated the efficacy of …